Cagrilintide
Long-Acting Amylin Receptor Agonist
Mechanism of Action
Long-acting acylated amylin analog. Amylin, normally co-secreted with insulin, signals satiety via the area postrema/brainstem; cagrilintide's fatty-acid-acylation and albumin binding (the same technology as semaglutide) extend this satiety signal, complementing GLP-1's separate appetite pathway.
Key Benefits
- Greater weight loss combined with semaglutide (CagriSema) than semaglutide alone (~20.4% vs ~3.0% placebo at 68 weeks, REDEFINE 1)
- Distinct amylin-pathway mechanism complements GLP-1 monotherapy
- Comparable overall safety profile to semaglutide monotherapy
- Improved waist circumference and blood pressure in combination therapy
Dosing Protocol
The overwhelming majority of efficacy/safety data is for the CagriSema combination with semaglutide, not cagrilintide monotherapy; titrate on a schedule similar to semaglutide.
Ideal Candidates
Adults with obesity or overweight with comorbidity, particularly those who plateaued on GLP-1 monotherapy alone.
Side Effects & Safety
GI adverse events (nausea, vomiting, diarrhea, constipation) more frequent than placebo, and more frequent than semaglutide alone in combination; injection site reactions.
Regulatory Status
Gray AreaInvestigational — not yet FDA-approved as monotherapy or as the CagriSema combination. Novo Nordisk's REDEFINE program is under regulatory review as of 2026. No 503A listing.
Evidence & Citations
Frequently asked
What is Cagrilintide?+
Cagrilintide (Long-Acting Amylin Receptor Agonist) is a peptide studied for amylin pathway and appetite suppression. Long-acting acylated amylin analog. Amylin, normally co-secreted with insulin, signals satiety via the area postrema/brainstem; cagrilintide's fatty-acid-acylation and albumin binding (the same technology as semaglutide) extend this satiety signal, complementing GLP-1's separate appetite pathway.
What is the dosing protocol for Cagrilintide?+
Literature commonly references 0.25 mg/wk (titration start) (low) to 2.4 mg/wk (maintenance) via SubQ weekly, on a ongoing cycle. Educational reference only — a licensed Stackhaus Health provider sets any personalized protocol.
What is the regulatory status of Cagrilintide?+
Investigational — not yet FDA-approved as monotherapy or as the CagriSema combination. Novo Nordisk's REDEFINE program is under regulatory review as of 2026. No 503A listing.
Where can I access Cagrilintide?+
Research-grade Cagrilintide is available through Stackhaus Research. For a personalized, provider-reviewed protocol, consult a licensed clinician through Stackhaus Health.
More in Weight Management
Used in these stacks
Cagrilintide appears in 1 research protocol in the Stackhaus Academy library.